Is there data from a head-to-head study for avacincaptad pegol vs pegcetacoplan?

Published

Prescribing Information including BOXED WARNING

There have not been any head to head studies comparing the safety or efficacy of avacincaptad pegol (ACP) to pegcetacoplan (PEG).

The safety and efficacy of ACP in patients with geographic atrophy secondary to age-related macular degeneration was assessed in two pivotal studies: GATHER1 and GATHER2, which were sham-controlled studies. Patients were excluded from the GATHER studies if they had undergone any prior intravitreal treatment for any indication in either eye, including PEG.^1–4

A literature search conducted in Biosis, Embase, and Medline on 11-NOV-2025 did not yield any results on direct treatment comparison studies for ACP and PEG. Please note while this is an extensive search, it is not all exhaustive.

Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021; 128.(4):576-586. Available at: https://doi.org/10.1016/j.ophtha.2020.08.027.
Jaffe GJ, Westby K, Csaky KG, et al. Supplement to: C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021; 128.(4):576-586. Available at: https://doi.org/10.1016/j.ophtha.2020.08.027.
Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023; 402.(10411):1449-1458. Available at: https://doi.org/10.1016/s0140-6736(23)01583-0.
Khanani AM, Patel SS, Staurenghi G, et al. Supplement to: Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023; 402.(10411):1449-1458. Available at: https://doi.org/10.1016/s0140-6736(23)01583-0.